Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinicopathological Characterization of HER2-Low-Expressing Triple-Negative Breast Cancer: Distinct Features From HER2-Zero Subtype.

Clinical breast cancer - 1 Jun 2026

Kato Michiko, Masuda Hiroko, Nakayama Sayuka, Ohara Jun, Kano Miharu, Suyama Karen, Yoshida Reika, Tsuruga Asako, Sasaki Yosuke, Takimoto Masafumi, Hayashi Naoki, Yamochi Toshiko

Abstract excerpt

BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive disease characterized by a poor prognosis and marked biological heterogeneity. Recently, HER2-low tumors have emerged as potential therapeutic targets. However, the clinical and biological significance of HER2-low TNBC remains unclear. METHODS: We retrospectively analyzed 195 patients with primary TNBC treated at our institution between April 2014...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Lymphocytes, Tumor-Infiltrating

Share to Prognosis

Share to Receptors, Androgen

Share to Triple Negative Breast Neoplasms

Source

Identifiers

PMID: 42185201
DOI: 10.1016/j.clbc.2026.04.008

Genes

AR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinicopathological Characterization of HER2-Low-Expressing Triple-Negative Breast Cancer: Distinct Features From HER2-Zero Subtype.PMID 42185201Read ↗

Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other BiomarkersSemantic proximity Read ↗

Clinicopathological features and prognosis of HER2 low-expression breast cancer: a single-center retrospective studySemantic proximity Read ↗

Molecular characteristics and prognosis of triple negative breast cancer stratified by HER2 status.Semantic proximity Read ↗

[Biological characteristics of triple negative breast cancer with low expression of HER2].Semantic proximity Read ↗

Clinical and molecular characteristics of HER2-low triple-negative breast cancer: insights from multi-omics analysisSemantic proximity Read ↗

Do HER2-Low Tumors Have a Distinct Clinicopathologic Phenotype?Semantic proximity Read ↗

Triple Negative Breast Cancer Subclassified by Immunohistochemistry: Correlation with Clinical and Pathological Outcomes in Patients Receiving Neoadjuvant ChemotherapySemantic proximity Read ↗

The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 statusSemantic proximity Read ↗

Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancerSemantic proximity Read ↗

Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.Semantic proximity Read ↗

Triple-negative breast cancer: unique biology and its management.Semantic proximity Read ↗

Molecular subtypes of triple-negative breast cancer: understanding of subtype categories and clinical implication.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.